Emergent BioSolutions Receives FDA Approval for BioThrax Administered Intramuscularly in a Three-Dose Primary Series ...
Emergent BioSolutions Inc. announced today that the U.S. Food and Drug Administration has approved its supplemental Biologics License Application to change the administration schedule of BioThrax to a three-dose primary series of intramuscular injections at 0, 1, and 6 months.

Fighting Fat: FDA Panel OKs Arena Diet Pill
In a move that may herald a new era in fighting fat, an FDA advisory voted 18-to-4 to recommend the agency approve the Arena Pharmaceutical diet pill, which is known as Lorqess. This marks the second time in three months that an FDA panel has decided the benefits of reducing the growing American waist line outweigh the various risks that have delayed this latest round of fat-fighting drugs from ...